에 대한 최신 뉴스 Edwards Lifesciences (NYSE:EW) 주식

Edwards Lifesciences

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.

Earnings

News

Pre-Market Outlook

Markets

금요일 아침 (현지 시간 기준) 미국 주식 선물이 약간 높게 거래되면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다: 1. 월스트리트는 오토네이션(NYSE:AN)이 개장 전 분기별 주당 순이익 $4.38와 매출 $67.1억 달러를 보고할 것으로 예상하고 있다. 오토네이션의 주식은 애프터 마켓에서 0.4% 상승하여 $163.81에 거래되었다.

금요일 주목해야 할 주식: 오토네이션, 캐피털 원, 콜게이트 그리고 2종목

Large Cap

Movers

DELL

LULU

MBLY

MEDP

SMCI

STLA

이들 12개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 에드워드 라이프사이언스(NYSE:EW)의 주가는 회사가 예상보다 나쁜 2분기 매출 실적을 보고하고 예상치보다 낮은 3분기 가이던스를 발표한 후 28.05% 급락했다. 회사는 또한 제나밸브(JenaValve)와 엔도트로닉스(Endotronix)를 인수했다. 몇몇 분석가들은 가격 전망을 대폭 낮췄다.

포드, 스텔란티스 및 델은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 21일부터 7월 27일)

Equities

Previews

Tech

Trading Ideas

ABBV

AGYS

ASML

BJRI

CHKP

CHTR

CMCSA

DECK

GATX

GOOG

GOOGL

JNPR

NFLX

NXPI

ODFL

ORLY

SKYW

SPOT

TSLA

VRSN

S&amp;P 500 기업들 중 약 14%가 6월 분기 실적을 발표했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.

테슬라, 알파벳, GM 및 포드가 이번 주 실적 발표 주도하며 상승세 유지 위해 고군분투

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences Corp

iShares MSCI Australia Index Fund

East West Bancorp Inc

EAST WEST BANKING CORP by EAST WEST BANKING CORPORATION

iShares MSCI Canada Index Fund

ENERGY WORLD CORP LTD by Energy World Corp. Ltd.

Energy World Corp Ltd

European Wax Center, Inc. - Class A Common Stock

European Wax Center Inc

iShares Inc iShares MSCI Sweden ETF

Global X Funds Emerging Mkts Internet & E- Commerce ETF (New)

iShares MSCI Germany Index Fund

EAT WELL INVT GROUP INC by Eat Well Investment Group Inc.

Eat Well Investment Group Inc

iShares Trust MSCI Germany Small-Cap ETF

iShares MSCI Hong Kong Index Fund

iShares Inc iShares MSCI Italy ETF

EDINBURGH WORLDWIDE INVES by Edinburgh Worldwide Investment Trust plc

iShares MSCI Japan Index Fund

iShares MSCI Japan Value ETF

iShares Inc iShares MSCI Belgium ETF

EARTHWORKS ENTMT NEW by Earthworks Entertainment, Inc.

Earthworks Entertainment Inc

iShares Inc iShares MSCI Switzerland ETF

EWELLNESS HEALTHCARE CORP by eWellness Healthcare Corp

eWellness Healthcare Corp

Merion Inc

iShares MSCI Malaysia Index Fund

iShares MSCI Netherlands Index Fund

iShares Inc iShares MSCI Austria ETF

EASTWOOD BIO-MED CDA INC by Eastwood Bio-Med CDA Inc.

iShares Inc iShares MSCI Spain ETF

EMERGING WORLD PHARMA INC by Emerging World Pharma, Inc.

Emerging World Pharma Inc

EAST WEST PETE ORD by East West Petroleum Corp.

East West Petroleum Corp

iShares MSCI France Index Fund

EWORLD COMPANIES INC by eWorld Companies, Inc.

eWorld Companies Inc

iShares Inc iShares MSCI Singapore ETF

EWSB Bancorp Inc

iShares Inc iShares MSCI Taiwan ETF

Energy Web - United States Dollar

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics Inc

iShares MSCI United Kingdom ETF

iShares MSCI United Kingdom Small Cap ETF

ProShares UltraShort MSCI Japan

iShares Inc iShares MSCI Mexico ETF

SPDR S&P Emerging Markets Small Cap ETF

iShares Inc iShares MSCI South Korea ETF

iShares Inc iShares MSCI Brazil ETF

iShares MSCI Brazil Small-Cap ETF

Wolfe Research analyst Mike Polark downgrades Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) from Peer Perform to Underperform and maintains the price target from $60 to $60.

Downgrades

Price Target

Analyst Ratings

Wolfe Research Downgrades Edwards Lifesciences to Underperform, Maintains Price Target to $60

20 analysts have shared their evaluations of Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $75.7, a high estimate of $90.00, and a low estimate of $63.00. Experiencing a 0.67% decline, the current average is now lower than the previous average price target of $76.21. 
<img src="https://www.benzinga.com/files/images/story/2024/1734379243_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Edwards Lifesciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$83.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$78.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$68.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$63.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$70.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$66.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$70.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$77.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$70.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Edwards Lifesciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Edwards Lifesciences compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Edwards Lifesciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Edwards Lifesciences analyst ratings.</a>
<h2>About Edwards Lifesciences</h2>
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
<h3>Edwards Lifesciences's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Positive Revenue Trend: Examining Edwards Lifesciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.93% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Edwards Lifesciences's net margin excels beyond industry benchmarks, reaching 226.73%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Edwards Lifesciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 36.16% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Edwards Lifesciences's ROA stands out, surpassing industry averages. With an impressive ROA of 26.62%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.07.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Edwards Lifesciences: Insights From 20 Financial Analysts

B of A Securities analyst Travis Steed upgrades Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) from Neutral to Buy and raises the price target from $82 to $90.

Upgrades

B of A Securities Upgrades Edwards Lifesciences to Buy, Raises Price Target to $90

Citigroup analyst Joanne Wuensch maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Buy and raises the price target from $81 to $83.

Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $83

Goldman Sachs analyst David Roman maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Buy and raises the price target from $81 to $90.

Goldman Sachs Maintains Buy on Edwards Lifesciences, Raises Price Target to $90

Truist Securities analyst Richard Newitter reiterates Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Hold and raises the price target from $70 to $78.

Reiteration

Truist Securities Reiterates Hold on Edwards Lifesciences, Raises Price Target to $78

Stifel analyst Rick Wise maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Hold and raises the price target from $70 to $75.

Stifel Maintains Hold on Edwards Lifesciences, Raises Price Target to $75

RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Outperform and raises the price target from $80 to $85.

RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $85

Canaccord Genuity analyst William Plovanic maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Hold and raises the price target from $63 to $68.

Canaccord Genuity Maintains Hold on Edwards Lifesciences, Raises Price Target to $68

On Wednesday, during its annual investor conference, Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) detailed its strategy for sustained long-term growth and innovations in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42310196/edwards-lifesciences-outlines-growth-strategy-at-annual-investor-conference" rel="noreferrer noopener">structural heart therapies</a>.
The company, now exclusively focused on structural heart solutions, emphasized its robust technology pipeline, financial guidance, and expanding opportunities in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT).
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42274583/morgan-stanley-maintains-positive-medtech-outlook-despite-setbacks-in-2024-upgrades-intuitive-surgical-and-stryker-downgrades-nevro-and-glaukos" rel="noreferrer noopener">Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos</a>
CEO Bernard Zovighian projected 2025 as another strong year, highlighting expected sales growth of 8% to 10%, driven by advancements in TAVR and TMTT technologies.
Zovighian underscored the company's commitment to improving patient care through innovative products, including the SAPIEN valve platform, PASCAL, and EVOQUE. He also pointed to new areas like Structural Heart Failure and Aortic Regurgitation (AR) as key opportunities for future growth.
Major Growth Drivers
<ul>
<li>Transcatheter Aortic Valve Replacement (TAVR) is projected to contribute $4.1 to $4.4 billion in 2025 sales, with constant currency growth of 5% to 7%.</li>
<li>The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment is forecasted to grow by 50% to 60% in 2025, with projected sales of $500 to $530 million.</li>
<li>Technologies such as the EVOQUE tricuspid valve and the PASCAL system will play pivotal roles, alongside the anticipated CE Mark approval for SAPIEN M3 in mid-2025 and U.S. approval by the first half of 2026.</li>
<li>Surgical Therapies: Edwards plans to expand the adoption of its RESILIA portfolio, which includes innovative solutions like INSPIRIS and KONECT. Emerging markets remain a focal point for delivering these technologies globally.</li>
<li>Zovighian emphasized expanding Edwards' presence in structural heart failure with the recent U.S. approval of the Cordella pulmonary artery pressure sensor.
<ul>
<li>The company anticipates stronger growth starting in 2026 and beyond, driven by its expanding range of structural heart therapies. It aims for an average annual sales growth of 10% and double-digit EPS growth: Mid-to-high single-digit growth fueled by EARLY TAVR and PROGRESS programs.</li>
<li>TMTT Expansion: Expected to contribute more, aiming for $2 billion in revenue by 2030.</li>
<li>New Therapies: Increased focus on areas like Structural Heart Failure and AR to drive future growth.</li>
</ul>
</li>
</ul>
Financial Outlook
<ul>
<li>Edwards projects total 2025 sales of $5.6 to $6 billion versus a consensus of $5.91 billion.</li>
<li>Adjusted earnings per share are expected to range from $2.40 to $2.50 compared to the consensus of $2.44, supported by gross profit margins of 78% to 79%.</li>
<li>The company reaffirmed its 2024 constant currency sales <a href="https://www.benzinga.com/calendars/guidance">growth guidance of 8% &#8211; 10%.</a></li>
</ul>
Price Action: EW stock is up 4.21% at $73.15 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/12/42317793/unitedhealth-introduces-2025-guidance-ahead-of-now-stopped-investor-conference" target="_blank" rel="noreferrer noopener">UnitedHealth Group Issued 2025 Guidance Ahead Of Now Stopped Investor Conference</a></li>
</ul>

Guidance

Health Care

General

Edwards Lifesciences Outlines Vision For Growth At Investor Conference

WIIM

Edwards Lifesciences shares are trading higher after company provided an updated FY25 guidance.

2025 Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Sales</td>
<td colspan="1" rowspan="1">
$5.6 - $6.0 billion
(8% - 10% constant currency growth)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">TAVR</td>
<td colspan="1" rowspan="1">
$4.1 - $4.4 billion
(5% - 7% constant currency growth)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">TMTT</td>
<td colspan="1" rowspan="1">
$500 - $530 million
(50% - 60% constant currency growth)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Surgical</td>
<td colspan="1" rowspan="1">
$970 million - $1.05 billion
(mid-single digit constant currency growth)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">FX Impact on Sales</td>
<td colspan="1" rowspan="1">
~$100 million unfavorable
(~2pt downside to reported growth)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Gross Profit Margin</td>
<td colspan="1" rowspan="1">78% - 79%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Operating Margin</td>
<td colspan="1" rowspan="1">27% - 28%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Tax Rate</td>
<td colspan="1" rowspan="1">15% - 18%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">$2.40 - $2.50</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diluted Shares Outstanding</td>
<td colspan="1" rowspan="1">585 – 595 million</td>
</tr>
</tbody>
</table>
</figure>
<ul>
<li>Increasing contribution from an expanding set of structural heart therapies in 2026 and beyond; targeting 10% average annual total company sales growth and double-digit EPS growth
<ul>
<li>Mid-to-high single digit TAVR growth driven by EARLY TAVR and PROGRESS</li>
<li>TMTT increasing contribution to growth, reaching $2 billion by 2030</li>
<li>Increasing contribution from new therapeutic areas including Structural Heart Failure and AR</li>
</ul>
</li>
</ul>

Edwards Lifesciences Expects 2025 Sales Of $5.6B-$6B Vs. Consensus Of $5.91B, With Adjusted EPS Of $2.40-$2.50 Versus Consensus Of $2.44, Reaffirms 2024 Constant Currency Sales Growth Guidance Of 8%-10%

Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to &#8220;Attractive,&#8221; believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong.
However, this view didn&#8217;t play out as expected, mainly due to unforeseen, company-specific issues, such as DexCom, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) unexpected <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39988466/dexcom-faces-short-term-challenges-but-market-growth-prospects-remain-strong-analys" rel="noreferrer noopener">Q2 channel mix challenges</a>, Edwards Lifesciences Corporation&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39967649/edwards-lifesciences-stock-tumbles-highlights-slowdown-in-tavr-business" rel="noreferrer noopener">slowdown in TAVR procedures</a>, TransMedics Group, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41608129/organ-transplant-medtech-transmedics-q3-performance-disappoints-analyst-outlines-in" rel="noreferrer noopener">seasonal impacts</a>, and iRhythm Technologies, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41462205/with-fda-approval-irhythm-may-be-able-to-lift-regulatory-overhang-investor-skeptici" rel="noreferrer noopener">DOJ investigation</a>.
Morgan Stanley is bullish on the MedTech industry as volumes and pipelines continue to be strong into 2025 despite a shakey 2024.
The analyst also adds that MedTech seems less exposed to potential delays from extended FDA regulatory pathways than other healthcare sectors, given its lower reliance on PMAs and clinical-trial-heavy products.
The analyst adds that while single-stock surprises are inevitable, the overall outlook for the sector heading into 2025 remains favorable.
Morgan Stanley upgraded the outlook on Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) and Stryker Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), moving both to Overweight from Equal-weight, citing:
<ul>
<li>ISRG: Strong demand for the Da Vinci Dv5 system is expected to exceed market expectations for <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41406234/intuitive-surgical-posts-q3-earnings-beat-these-analysts-raise-forecasts-on-dv5-upt" target="_blank" rel="noreferrer noopener">installed base growth</a>.</li>
<li>SYK: While orthopedic procedure volumes face some uncertainty, an estimated $1 billion—$2 billion backlog could drive growth in 2025. The company also benefits from ongoing M&amp;A opportunities <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40819730/stryker-unveils-new-foot-ankle-solutions-with-truss-implants-details" target="_blank" rel="noreferrer noopener">and product innovations</a>.</li>
</ul>
Additional updates:
<ul>
<li>Procept BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>): Initiated at Overweight, driven by increasing demand and higher pricing for Hydros in operating room efficiency, particularly in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41583831/surgical-robotics-provider-procept-biorobotics-q3-earnings-beats-street-view-analys" target="_blank" rel="noreferrer noopener">lower-volume BPH centers</a>.</li>
<li>Tandem Diabetes Care Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>): Upgraded to Overweight with a $45 price target, as its valuation (below 2x sales) seems overly compressed. Expansion into type 2 diabetes in 2025 could double its <a href="https://www.benzinga.com/news/24/10/41148635/tandem-diabetes-insulin-pump-demand-to-surge-despite-popular-demand-of-weight-loss-drugs-bullish-ana" target="_blank" rel="noreferrer noopener">total addressable market</a>.</li>
<li>Globus Medical Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>): Upgraded to Overweight with a $100 price target as merger concerns ease and strong above-market growth persists.</li>
<li>Embecta Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>): Raised to Equal-weight from Underweight, factoring in the discontinuation of certain risks and potential upside from GLP-1 <a href="https://www.benzinga.com/news/24/10/41148635/tandem-diabetes-insulin-pump-demand-to-surge-despite-popular-demand-of-weight-loss-drugs-bullish-ana" target="_blank" rel="noreferrer noopener">pen needle demand</a>.</li>
</ul>
The analyst is more cautious about Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), downgrading it to Underweight from Equal-weight. The analyst notes that iDose is a strong product with promising long-term potential, but the current valuation limits the upside compared to other stocks. Additionally, although the pipeline includes exciting projects like Wet AMD, they remain <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41752463/glaukos-reports-30-boost-in-glaucoma-sales-improved-margins-in-q3-analyst-highlights-certain-headwi" rel="noreferrer noopener">years away from fruition</a>.
Morgan Stanley has downgraded Nevro Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) to Underweight from Equal-weight. Despite trading near record lows, the analyst expects weak demand for spinal cord stimulation devices to persist, with limited <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41910770/why-medical-device-firm-nevro-stock-is-trading-higher-on-tuesday" rel="noreferrer noopener">opportunities for cost reductions</a>.
The analyst remains cautious about STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>). While the company is executing well, it faces tough conditions in the refractive surgery market, particularly in China and the U.S.
Lastly, Morgan Stanley is cautious about Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) because it offers fewer upside opportunities than peers and has a more conservative outlook <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41845345/baxter-expects-hurricane-helene-aftermath-to-impact-near-term-financial-outlook" rel="noreferrer noopener">on operating margins</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42270388/marvell-and-aws-deepen-collaboration-on-cloud-and-ai-solutions-driving-stock-surge-ahead-of-q3-earnings" target="_blank" rel="noreferrer noopener">Marvell And AWS Deepen Collaboration On Cloud And AI Solutions: Details</a></li>
</ul>
Photo by metamorworks via Shutterstock

Analyst Color

Biotech

DXCM

EMBC

GKOS

GMED

IRTC

ISRG

NVRO

PRCT

STAA

TMDX

TNDM

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Analysts' ratings for Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">11</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Edwards Lifesciences, revealing an average target of $73.71, a high estimate of $90.00, and a low estimate of $63.00. This current average represents a 7.72% decrease from the previous average price target of $79.88. 
<img src="https://www.benzinga.com/files/images/story/2024/1732730466_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Edwards Lifesciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$63.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$70.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$66.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$70.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$77.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$70.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$71.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Edwards Lifesciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Edwards Lifesciences compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Edwards Lifesciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Edwards Lifesciences's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Edwards Lifesciences analyst ratings.</a>
<h2>Get to Know Edwards Lifesciences Better</h2>
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
<h3>Edwards Lifesciences: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Edwards Lifesciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.93% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 226.73%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Edwards Lifesciences's ROE excels beyond industry benchmarks, reaching 36.16%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Edwards Lifesciences's ROA stands out, surpassing industry averages. With an impressive ROA of 26.62%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below the industry average. With a ratio of 0.07, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Edwards Lifesciences In The Eyes Of 17 Experts

RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Outperform and raises the price target from $75 to $80.

RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $80

Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.
An analysis of data from more than 9,000 propensity-matched patients in the STS/ACC TVT Registry1 demonstrated that those who received Edwards' newest generation SAPIEN 3 Ultra RESILIA valve experienced outstanding one-year outcomes that continuously surpassed recipients of the earlier generation SAPIEN 3 and SAPIEN 3 Ultra valves. Patients receiving the SAPIEN 3 Ultra RESILIA valve experienced extremely low mortality, low rates of reintervention, larger effective orifice areas, lower echo-derived gradients across all valve sizes and no paravalvular leak in 84.4% of cases.
"These strong, real-world data continue to demonstrate that patients treated with a SAPIEN valve experience excellent outcomes with rapid recovery and improved quality of life," said Larry Wood, Edwards' corporate vice president and group president, transcatheter aortic valve replacement and surgical structural heart. "These data add to the immense body of evidence with multiple years of follow up on the Edwards SAPIEN valve platform and more than 10 years of clinical experience with the RESILIA tissue."
Patients in the SAPIEN 3 Ultra RESILIA valve cohort, who had an average STS score of 3.6 and average age of 77, experienced meaningful quality of life benefits with a clinically significant average 31-point increase in KCCQ2 score and one-day length of hospital stay with 93% discharged to their homes.
"This is the first large-population study that showed the latest generation SAPIEN 3 Ultra RESILIA valve results in improved 1-year survival after TAVR versus prior generation valves, given it reduces mild or greater paravalvular leak," said Gilbert Tang, MD, MSc, MBA, Surgical and Academic Director of the Structural Heart Program for the Mount Sinai Health System and Professor and Vice-Chair of Innovation in Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai. "This finding particularly affected low surgical risk patients, where the impact would matter more because of their longer life expectancies."
Dr. Tang is a consultant for Edwards Lifesciences. 1 The STS/ACC TVT Registry is a collaboration between the Society of Thoracic Surgeons (STS) and the American College of Cardiology (ACC). 2 The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item survey that measures the impact of heart failure on a patient's quality of life, symptoms, and physical function.

Edwards Lifesciences' SAPIEN 3 Ultra RESILIA Valve Shows One-Year Outcomes: Data Presented at PCR London Valves

On Wednesday,&nbsp;Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) released the results of the primary endpoint of the ACURATE IDE trial of&nbsp;ACURATE&nbsp;neo2 Aortic Valve System for patients with severe, symptomatic aortic stenosis at risk of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41629382/acurate-neo2-aortic-valve-system-data-presented-at-late-breaking-clinical-trial-session-at-tct-202" rel="noreferrer noopener">open-heart surgery</a>.
The data were presented at Transcatheter Cardiovascular Therapeutics 2024, the annual scientific symposium of the Cardiovascular Research Foundation.
This randomized trial evaluated the ACURATE&nbsp;neo2 valve, the company&#8217;s second-generation transcatheter aortic valve replacement (TAVR) technology, versus a pre-defined control valve, either the commercially available SAPIEN valve or the Evolut transcatheter aortic valve system.
SAPIEN valve is sold by Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), and Evolut is Medtronic Plc&#8217;s NYSE: MDT) brand.
The composite rate of all-cause mortality, stroke, or rehospitalization at one year was 16.16% in the ACURATE&nbsp;neo2 arm and 9.53% in the control arm, not meeting the prespecified criterion for non-inferiority (the posterior probability for non-inferiority was 77.9%, which is lower than the non-inferiority test threshold of 97.5%).
&#8220;This trial is the largest randomized comparison of TAVR platforms and was conducted over four years, including during a global pandemic that introduced complexities for enrollment,&#8221; said&nbsp;Michael Reardon, co-principal investigator of the ACURATE IDE trial.
The company also presented data from a post-hoc analysis to identify and evaluate expanded and under-expanded ACURATE&nbsp;neo2 valve frames within the ACURATE IDE trial.
The company reviewed key procedural factors, including pre-and post-dilation, which help prepare for, enable, and confirm proper valve expansion during the procedure.
Following this review, an assessment of implant quality for the ACURATE&nbsp;neo2 valve was initiated. The assessment highlighted that approximately 20% of the valves were under-expanded.
Data from the assessment also demonstrated that the rate of death, stroke, or rehospitalization at one year was similar between the ACURATE&nbsp;neo2 expanded group and the control group.
Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S.
The ACURATE&nbsp;neo2 Aortic Valve System and the ACURATE Prime Aortic Valve System are approved in Europe.
In the&nbsp;U.S., the ACURATE&nbsp;neo2 Aortic Valve System and the ACURATE Prime Aortic Valve System are investigational devices.
Price Action: BSX stock is down 1.66% at $83.16 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41630458/cdw-shares-dip-as-q3-sales-miss-amid-weak-hardware-demand-and-customer-delays" target="_blank" rel="noreferrer noopener">CDW Shares Dip As Q3 Sales Miss Amid Weak Hardware Demand And Customer Delays</a></li>
</ul>

Why is Boston Scientific Stock Trading Lower On Wednesday?

<a href="https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk" title="https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk">https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk</a>

Shares Of Boston Scientific See Volume; Company To Provide Cardiology Business Update At 4:00 PM EDT

TRISCEND II Trial Shows Edwards EVOQUE System Significantly Outperforms Medical Therapy Alone In Treating Severe Tricuspid Regurgitation, Achieving 95.3% TR Elimination And Marked Improvements In Symptoms And Quality Of Life At One Year; Results Published In NEJM And JACC

Benzinga's options scanner has just identified more than 10 option transactions on Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), with a cumulative value of $336,522. Concurrently, our algorithms picked up 2 puts, worth a total of 107,477.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $67.5 to $82.5 for Edwards Lifesciences during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Edwards Lifesciences's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Edwards Lifesciences's whale trades within a strike price range from $67.5 to $82.5 in the last 30 days. 
<h3>Edwards Lifesciences Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730132130_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.0</td>
<td>$3.8</td>
<td>$3.8</td>
<td>$72.50</td>
<td>$69.9K</td>
<td>326</td>
<td style="text-align: right;">185</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.3</td>
<td>$70.00</td>
<td>$45.5K</td>
<td>407</td>
<td style="text-align: right;">268</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.5</td>
<td>$3.3</td>
<td>$3.5</td>
<td>$70.00</td>
<td>$43.0K</td>
<td>407</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.3</td>
<td>$2.25</td>
<td>$2.3</td>
<td>$67.50</td>
<td>$37.5K</td>
<td>1.0K</td>
<td style="text-align: right;">163</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.95</td>
<td>$1.3</td>
<td>$2.0</td>
<td>$77.50</td>
<td>$30.0K</td>
<td>913</td>
<td style="text-align: right;">150</td>
</tr>
</tbody>
</table>

<h3>About Edwards Lifesciences</h3>
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
In light of the recent options history for Edwards Lifesciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Edwards Lifesciences</h3>
<ul>
<li>Currently trading with a volume of 4,192,400, the EW's price is up by 0.08%, now at $69.43. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 99 days.</li>
</ul>
<h3>Expert Opinions on Edwards Lifesciences</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $72.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Edwards Lifesciences, which currently sits at a price target of $75. 
&#x2A; An analyst from Piper Sandler persists with their Neutral rating on Edwards Lifesciences, maintaining a target price of $70. 
&#x2A; An analyst from Morgan Stanley downgraded its action to Equal-Weight with a price target of $70. 
&#x2A; An analyst from JP Morgan has decided to maintain their Neutral rating on Edwards Lifesciences, which currently sits at a price target of $78. 
&#x2A; An analyst from Baird has decided to maintain their Neutral rating on Edwards Lifesciences, which currently sits at a price target of $68. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Edwards Lifesciences, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Unpacking the Latest Options Trading Trends in Edwards Lifesciences

Bernstein analyst Lee Hambright raised the firm's price target on Edwards Lifesciences (EW) to $74 from $72 and keeps a Market Perform rating on th...

Edwards Lifesciences price target raised to $74 from $72 at Bernstein

Bullish option flow detected in Edwards Lifesciences (EW) with 7,599 calls trading, 2x expected, and implied vol increasing almost 3 points to 45.2...

Edwards Lifesciences call volume above normal and directionally bullish

In a report released yesterday, Lee Hambright from Bernstein maintained a Hold rating on Edwards Lifesciences (EW – Research Report). The company's...

Bernstein Reaffirms Their Hold Rating on Edwards Lifesciences (EW)

Citi analyst Joanne Wuensch maintained a Buy rating on Edwards Lifesciences (EW – Research Report) today. The company's shares closed yesterday at ...

Citi Reaffirms Their Buy Rating on Edwards Lifesciences (EW)

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core transcatheter ...

Edwards Lifesciences downgraded to Underperform at Wolfe Research

Wedgewood Partners Q4 2024 Client Letter

Wedgewood Partners: Q4 And 2024 Top Performers And Detractors

Edwards Lifesciences downgraded at Wolfe on TAVR worries

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: UnitedHealth (UNH) reported upbeat Q4 ...

UnitedHealth, BofA report Q4 earnings beats: Morning Buzz

What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during...

Comments

Edwards Lifesciences

뉴스

에 대한 최신 뉴스 Edwards Lifesciences (NYSE:EW) 주식

금요일, 10월 25, 2024

월요일, 7월 29, 2024

일요일, 7월 21, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌